Symphysis Medical

Independence | Comfort | Quality of Life

Developing an innovative drainage technology to treat malignant pleural effusions (MPE)

Read more...
Better Outcomes

Better
Outcomes

 

Incorporates an active component that will significantly shorten the treatment duration of MPE compared to current catheter devices.

 

Patient Centric

Patient
Centric

A user-friendly design to promote patient independence, comfort and quality of life.


Cost Effective

Healthcare
Savings

Reduces the costs associated with long-term home drainage and acute readmissions to hospital.


 

SymPhysis Medical

Located in Galway, Ireland

 

linked to experts internationally

 

SymPhysis Medical receive multiple nomin…

Posted in News by Nate Reynolds

20th November, 2023

November is proving to be a fruitful month this year as SymPhysis Medical have been nominated for not one but three awards. Firstly, the Excellence in Innovation Award is a part...

Read more

Symphysis Medical lead the charge in Inn…

Posted in News by Nate Reynolds

15th November, 2023

Last month, a number of client companies of ATU iHubs came together to host an onsite comedy show in aid of the National Breast Cancer Research Institute as part of...

Read more

SymPhysis Medical win “Innovation of t…

Posted in News by Nate Reynolds

19th July, 2023

SymPhysis Medical were thrilled to win the “Innovation of the Year” award at the Life Sciences Industry Awards which took place in Dublin on 7 July, 2023. Tim Jones and...

Read more

SymPhysis Medical nominated for Innovati…

Posted in News by Nate Reynolds

14th June, 2023

In May 2023, SymPhysis Medical was delighted to be nominated for Innovation of the Year Award in the inaugural year of The Life Science Industry Awards for its first drainage...

Read more

MPE By Numbers

Mesothelioma

Affects ~90% of patients with mesothelioma.

Lung Cancer

Affects ~ 35% of patients with lung cancer.

Breast Cancer

Affects ~ 16% of patients with breast cancer.

Lymphoma

Affects ~ 11% of patients with lymphoma.